John A. Auchampach, PhD
Principal Investigator; Professor, Vice Chair, Pharmacology and Toxicology
Dr. Auchampach is a professor in the Department of Pharmacology. He leads an NIH-funded laboratory focused on ischemic heart disease, cardiac regeneration, and drug development.
Tina Wan, PhD
Our laboratory studies adenosine signaling via its four G protein-coupled receptors during cardiovascular disease. We utilize mice and rats as our model system. I am involved in generating and characterizing new genetic mouse models with global and tissue-specific deletion of specific adenosine receptor subtypes. Other important aspects of my research involve assessing cardiac function (pressure-volume analyses; echocardiography) and conducting surgeries to induce myocardial infarction in rodents. Our laboratory has recently formed a new collaboration with Dr. John Lough in the Department of Cell Biology. The goal of this project using novel genetic mouse models is to test the hypothesis that inhibition of the acetyl transferase Tip60 during myocardial infarction will promote more efficient regeneration by permitting surviving cardiomyocytes to re-enter the cell cycle.
Elizabeth Gizewski, BS
Research Technologist III
I received my Degree from the University of Wisconsin-Madison. I have been working with Dr. Auchampach’s research group for the past 10 years. My role has been to characterize new synthetic ligands for adenosine receptors utilizing various biochemical assays including radioligand binding, cAMP accumulation, and [35S]GTPγS binding assays. I have made several important contributions to our research program working with research chemists at the NIH and Leiden University in the Netherlands. I have assisted with the development of new selective agonists for the A3 adenosine receptor, which have promise as drug therapy for many different inflammatory disorders and chronic neuropathic pain. I have also contributed to the development and characterization of an exciting new class of ligands for the A3 adenosine receptor called positive A3 adenosine receptor allosteric modulators.
Shraddha Nayak, BS
Graduate Research Assistant
I am a PhD graduate student in the Department of Pharmacology completing my thesis work in Dr. Auchampach’s laboratory. My project involves characterizing a new line of rats in which the A2B adenosine receptor gene has been genetically disrupted using the zinc finger nuclease strategy. The rat line was created on the Dahl salt-sensitive genetic background. My work has led to better understanding of the participation of A2B adenosine receptor signaling during cardiovascular diseases including hypertension and diabetes.
(Wang X, Lauth A, Wan TC, Lough JW, Auchampach JA.) Dis Model Mech. 2020 Dec 18;13(12) PMID: 33106234 PMCID: PMC7758623 SCOPUS ID: 2-s2.0-85098138727 10/28/2020
(Tosh DK, Salmaso V, Rao H, Campbell R, Bitant A, Gao ZG, Auchampach JA, Jacobson KA.) ACS Med Chem Lett. 2020 Oct 08;11(10):1935-1941 PMID: 33062176 PMCID: PMC7549272 10/17/2020
(Flinn MA, Otten C, Brandt ZJ, Bostrom JR, Kenarsary A, Wan TC, Auchampach JA, Abdelilah-Seyfried S, O'Meara CC, Link BA.) Development. 2020 Aug 25;147(16) PMID: 32843528 PMCID: PMC7473637 SCOPUS ID: 2-s2.0-85089923843 08/28/2020
(Tosh DK, Salmaso V, Rao H, Bitant A, Fisher CL, Lieberman DI, Vorbrüggen H, Reitman ML, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA.) J Med Chem. 2020 04 23;63(8):4334-4348 PMID: 32271569 PMCID: PMC7443318 SCOPUS ID: 2-s2.0-85083291207 04/10/2020
(Wan TC, Tampo A, Kwok WM, Auchampach JA.) Biochem Pharmacol. 2019 05;163:21-31 PMID: 30710517 PMCID: PMC6470012 SCOPUS ID: 2-s2.0-85061006338 02/03/2019
(Tosh DK, Rao H, Bitant A, Salmaso V, Mannes P, Lieberman DI, Vaughan KL, Mattison JA, Rothwell AC, Auchampach JA, Ciancetta A, Liu N, Cui Z, Gao ZG, Reitman ML, Gavrilova O, Jacobson KA.) J Med Chem. 2019 02 14;62(3):1502-1522 PMID: 30605331 PMCID: PMC6467784 SCOPUS ID: 2-s2.0-85059756838 01/04/2019
(Wodsedalek DJ, Paddock SJ, Wan TC, Auchampach JA, Kenarsary A, Tsaih SW, Flister MJ, O'Meara CC.) Am J Physiol Heart Circ Physiol. 2019 01 01;316(1):H24-H34 PMID: 30339498 SCOPUS ID: 2-s2.0-85060194313 10/20/2018
(Yu J, Mannes P, Jung YH, Ciancetta A, Bitant A, Lieberman DI, Khaznadar S, Auchampach JA, Gao ZG, Jacobson KA.) Medchemcomm. 2018 Nov 01;9(11):1920-1932 PMID: 30568760 PMCID: PMC6256369 12/21/2018
(Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA.) ACS Omega. 2018 Oct 31;3(10):12658-12678 PMID: 30411015 PMCID: PMC6210068 11/10/2018
(Carlin JL, Jain S, Duroux R, Suresh RR, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML.) Neuropharmacology. 2018 09 01;139:268-278 PMID: 29548686 PMCID: PMC6067974 SCOPUS ID: 2-s2.0-85043451256 03/20/2018
(Du L, Gao ZG, Paoletta S, Wan TC, Gizewski ET, Barbour S, van Veldhoven JPD, IJzerman AP, Jacobson KA, Auchampach JA.) Purinergic Signal. 2018 03;14(1):59-71 PMID: 29170977 PMCID: PMC5842153 SCOPUS ID: 2-s2.0-85034734757 11/25/2017
(Duroux R, Ciancetta A, Mannes P, Yu J, Boyapati S, Gizewski E, Yous S, Ciruela F, Auchampach JA, Gao ZG, Jacobson KA.) Medchemcomm. 2017 Aug 01;8(8):1659-1667 PMID: 29250307 PMCID: PMC5729930 12/19/2017